Prophylaxis of Thrombembolism
prophylaxis and treatment of thombembolic disorders
32311448 ä. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
32367471 ä. Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies
32330428 ä. Hospital-based use of thromboprophylaxis in patients with COVID-19
32361513 ä. Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
32339221 2020. COVID-19 and its implications for thrombosis and anticoagulation
32304577 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action
32352633 2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients
32339025 2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend
32311843 2020. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2
32239799 2020. The versatile heparin in COVID-19
32338827 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19
32302462 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment
32302442 2020. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19
32220112 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
32302451 2020. Response to Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
| 32329231 2020. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience |
32329221 2020. Type and dose of heparin in Covid-19: Reply
32329246 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19
32294321 2020. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis
32282993 2020. DOACs and newer haemophilia therapies in COVID-19
32281766 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?
32349133 2020. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge
32349132 2020. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
32316065 2020. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines
32267998 2020. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series
32378044 ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment
| 32387623 ä. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 |
C7183940 ä. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32297089 ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
32278361 ä. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
32307014 2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19
32449242 2020. Prevention of thrombosis in pregnant women with suspected SARS-CoV-2 infection: clinical management algorithm.
